PATIENT AND PHYSICIAN SATISFACTION OF TREATMENT WITH ECULIZUMAB OR RAVULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM A REAL-WORLD DISEASE-SPECIFIC PROGRAMME

被引：0
|
作者：
Fureder, W. [1 ]
Mellor, J. [2 ]
Earl, L. [2 ]
Wang, A. [3 ]
Patel, Y. [1 ,3 ]
Myren, K. J. [1 ,3 ]
Nagalla, S. [4 ]
机构：
[1] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med I, Vienna, Austria
[2] Adelphi Real World, Bollington, England
[3] Alexion, Boston, MA USA
[4] Miami Canc Inst, Benign Hematol, Miami, FL USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR187
引用
收藏
页码：S347 / S347
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD EFFECTIVENESS OF ECULIZUMAB, SWITCH TO RAVULIZUMAB AND RAVULIZUMAB AS FIRST THERAPY IN SWISS PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Rovo, A.
    Simeon, L.
    Gavillet, M.
    Samii, K.
    Cantoni, N.
    Drexler, B.
    Stussi, G.
    Bissig, M.
    [J]. SWISS MEDICAL WEEKLY, 2023, 153 : 30S - 31S
  • [2] Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry
    Hoechsmann, Britta
    de Fontbrune, Flore Sicre
    Lee, Jong Wook
    Kulagin, Alexander D.
    Hillmen, Peter
    Wilson, Amanda
    Marantz, Jing L.
    Schrezenmeier, Hubert
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (03) : 197 - 204
  • [3] Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab
    Kang, Ka-Won
    Moon, Hyemi
    Lee, Byung-Hyun
    Jeon, Min Ji
    Yu, Eun Sang
    Kim, Dae Sik
    Lee, Se Ryeon
    Sung, Hwa Jung
    Kim, Seok Jin
    Choi, Chul Won
    Kim, Byung Soo
    Lee, Juneyoung
    Park, Yong
    [J]. BLOOD, 2019, 134
  • [4] Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab in the UK
    Peipert, J. Devin
    Griffin, M.
    Kulasekararaj, A.
    Yount, S.
    Martens, C.
    Sparling, A.
    Webster, K. A.
    Cella, D.
    Tomazos, I.
    Ogawa, M.
    Yu, J.
    Hill, A.
    Kaiser, K.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 143 - 144
  • [5] REAL-WORLD DOSING PATTERNS OF ECULIZUMAB-NAIVE AND ECULIZUMAB-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING RAVULIZUMAB IN THE US
    Cheng, W. Y.
    Fishman, J.
    Yenikomshian, M.
    Mahendran, M.
    Kunzweiler, C.
    Vu, J. D.
    Duh, M. S.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S493 - S493
  • [6] Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
    Cheng, Wendy Y.
    Fishman, Jesse
    Sarda, Sujata P.
    Krishnan, Sangeeta
    Kunzweiler, Colin
    Vu, Jensen Duy
    Yenikomshian, Mihran
    Duh, Mei Sheng
    [J]. BLOOD, 2021, 138
  • [7] Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria
    Broderick, Kelly C.
    Burke, James P.
    Fishman, Jesse
    Gleason, Patrick P.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (08): : 941 - 951
  • [8] Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
    Cheng, Wendy Y.
    Sarda, Sujata P.
    Mody-Patel, Nikita
    Krishnan, Sangeeta
    Yenikomshian, Mihran
    Scoble, Patrick J.
    Kunzweiler, Colin
    Vu, Jensen Duy
    Cheung, Hoi Ching
    Duh, Mei Sheng
    [J]. BLOOD, 2020, 136
  • [9] The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
    David Dingli
    Joana E. Matos
    Kerri Lehrhaupt
    Sangeeta Krishnan
    Michael Yeh
    Jesse Fishman
    Sujata P. Sarda
    Scott B. Baver
    [J]. Annals of Hematology, 2022, 101 : 251 - 263
  • [10] The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
    Dingli, David
    Matos, Joana E.
    Lehrhaupt, Kerri
    Krishnan, Sangeeta
    Yeh, Michael
    Fishman, Jesse
    Sarda, Sujata P.
    Baver, Scott B.
    [J]. ANNALS OF HEMATOLOGY, 2022, 101 (02) : 251 - 263
12345